Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 11;14(7):742.
doi: 10.3390/jpm14070742.

The Role of Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in Recurrent Ovarian Peritoneal Carcinomatosis

Pirilti Özcan  1 , Özgül Düzgün  2
Affiliations

The Role of Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in Recurrent Ovarian Peritoneal Carcinomatosis

Pirilti Özcan et al. J Pers Med. .

Abstract

Background and aims: Ovarian cancer maintains the highest mortality rate among gynecological malignancies. Unfortunately, two-thirds of cases are diagnosed at an advanced stage with the presence of peritoneal carcinomatosis. In this study, we aimed to present the 7-year results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in cases where peritoneal carcinomatosis developed during the medical oncological treatment and follow-up after primary high-grade serous ovarian cancer debulking surgeries.

Patients and methods: Data from 63 patients collected prospectively in our clinic were retrospectively evaluated.

Results: Postoperative Clavien-Dindo grade 3-4 complications occurred in 12 cases (19%) and 14 cases (22.2%), respectively. CD grade 3a complications developed in four cases (6.3%), which were treated with percutaneous drainage catheters, while CD grade 3b complications occurred in eight cases (12.7%), and these cases underwent reoperation. Five cases (7.9%) experienced mortality within the first 30 days. The mean survival time was determined as 44.99 months (36.33-53.65), while the median survival time was 56 months.

Conclusions: In selected patients requiring redo surgery due to recurrent ovarian cancer, secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with longer overall survival and should be considered in the treatment of advanced-stage disease. Further large-scale randomized controlled trials are needed in this regard.

Keywords: ovarian cancer; peritoneal carcinomatosis; recurrent; secondary cytoreductive surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Overall Survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Picard L., Bourgin C., Penault-Llorca F., Beguinot M., Cornou C., Le Bouedec G., Mouret-Reynier M.A., Selle F., Pomel C. HIPEC in ovarian cancer: What should we expect? Bull. Cancer. 2019;106:1023–1028. doi: 10.1016/j.bulcan.2019.04.003. - DOI - PubMed
    1. Sugarbaker P.H. Optimizing regional chemotherapy for epithelial ovarian cancer. J. Obstet. Gynaecol. Res. 2022;48:1306–1317. doi: 10.1111/jog.15224. - DOI - PubMed
    1. Sugarbaker P.H., Van der Speeten K. Ovarian cancer with peritoneal metastases has many treatment options and HIPEC is here to stay. J. Gastrointest. Oncol. 2021;12((Suppl. 1)):S189–S190. doi: 10.21037/jgo-2020-17. - DOI - PMC - PubMed
    1. Cianci S., Riemma G., Ronsini C., De Franciscis P., Torella M., Schiattarella A., La Verde M., Colacurci N. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer recurrence: Systematic review and meta-analysis. Gland. Surg. 2020;9:1140–1148. doi: 10.21037/gs-20-335. - DOI - PMC - PubMed
    1. Tsuyoshi H., Inoue D., Kurokawa T., Yoshida Y. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer. J. Obstet. Gynaecol. Res. 2020;46:1661–1671. doi: 10.1111/jog.14391. - DOI - PubMed

LinkOut - more resources